BCAB Long Put Strategy
BCAB (BioAtla, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
BCAB (BioAtla, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $5.2M, a beta of 0.79 versus the broader market, a 52-week range of 3.92-71.5, average daily share volume of 40K, a public-listing history dating back to 2020, approximately 61 full-time employees. These structural characteristics shape how BCAB stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.79 places BCAB roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a long put on BCAB?
A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration.
Current BCAB snapshot
As of May 15, 2026, spot at $4.28, ATM IV 59.20%, IV rank 8.41%, expected move 16.97%. The long put on BCAB below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 63-day expiry.
Why this long put structure on BCAB specifically: BCAB IV at 59.20% is on the cheap side of its 1-year range, which favors premium-buying structures like a BCAB long put, with a market-implied 1-standard-deviation move of approximately 16.97% (roughly $0.73 on the underlying). The 63-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated BCAB expiries trade a higher absolute premium for lower per-day decay. Position sizing on BCAB should anchor to the underlying notional of $4.28 per share and to the trader's directional view on BCAB stock.
BCAB long put setup
The BCAB long put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With BCAB near $4.28, the first option leg uses a $4.28 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed BCAB chain at a 63-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 BCAB shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Put | $4.28 | N/A |
BCAB long put risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium.
BCAB long put payoff curve
Modeled P&L at expiration across a range of underlying prices for the long put on BCAB. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use long put on BCAB
Long puts on BCAB hedge an existing long BCAB stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying BCAB exposure being hedged.
BCAB thesis for this long put
The market-implied 1-standard-deviation range for BCAB extends from approximately $3.55 on the downside to $5.01 on the upside. A BCAB long put expresses a directional view that the underlying closes below the strike minus premium at expiration, frequently sized to hedge an existing long BCAB position with one put per 100 shares held. Current BCAB IV rank near 8.41% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on BCAB at 59.20%. As a Healthcare name, BCAB options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to BCAB-specific events.
BCAB long put positions are structurally bearish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. BCAB positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move BCAB alongside the broader basket even when BCAB-specific fundamentals are unchanged. Long-premium structures like a long put on BCAB are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current BCAB chain quotes before placing a trade.
Frequently asked questions
- What is a long put on BCAB?
- A long put on BCAB is the long put strategy applied to BCAB (stock). The strategy is structurally bearish: A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration. With BCAB stock trading near $4.28, the strikes shown on this page are snapped to the nearest listed BCAB chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are BCAB long put max profit and max loss calculated?
- Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium. For the BCAB long put priced from the end-of-day chain at a 30-day expiry (ATM IV 59.20%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a BCAB long put?
- The breakeven for the BCAB long put priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current BCAB market-implied 1-standard-deviation expected move is approximately 16.97%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long put on BCAB?
- Long puts on BCAB hedge an existing long BCAB stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying BCAB exposure being hedged.
- How does current BCAB implied volatility affect this long put?
- BCAB ATM IV is at 59.20% with IV rank near 8.41%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.